eli lilly glp-1 drug FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - The U.S. Food and Drug

It cannot establish a safe or effective human outcome

The core problem is simple but critical

Reported half-life Not applicable here - GHK-Cu isn't characterised as a dosed medicine, so there's no clinical half-life to quote

There is: No evidence that Epitalon can shrink existing tumors in humans No human clinical trials testing its use in oncology No mechanistic studies confirming how Epitalon affects tumor microenvironments or immune evasion in vivo What we do have is a compelling preventive profile in animal models, especially where aging and genetic susceptibility intersect

It acts as a highly selective agonist at receptors of the incretins GLP-1 and GIP, thereby increasing the amount of insulin released in a glucose-dependent manner